Uncategorized

Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan

Nicox SA, an international ophthalmology company, announced that new nonclinical data on NCX 470 demonstrating greater intraocular pressure lowering than Lumigan® upon both single and repeated dosing in an in vivo nonclinical model has been published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan Read More »

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock – December 14, 2023

Ocular Therapeutix™, Inc. announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock – December 14, 2023 Read More »

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China’s National Reimbursement Drug List

Antengene Corporation Limited announced that XPOVIO® has been added to the National Reimbursement Drug List for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease is refractory to at least one proteasome inhibitors, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China’s National Reimbursement Drug List Read More »

Scroll to Top